Bausch & Lomb Analyst Ratings
Bausch & Lomb Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/06/2023 | 22.48% | HC Wainwright & Co. | $22 → $21 | Reiterates | Buy → Buy |
| 10/03/2023 | 16.65% | Evercore ISI Group | → $20 | Reinstates | → Outperform |
| 08/04/2023 | 28.32% | HC Wainwright & Co. | → $22 | Reiterates | Buy → Buy |
| 08/03/2023 | 16.65% | Morgan Stanley | $20 → $20 | Reiterates | Equal-Weight → Equal-Weight |
| 08/03/2023 | 10.82% | Barclays | $18 → $19 | Maintains | Equal-Weight |
| 07/24/2023 | 22.48% | RBC Capital | $20 → $21 | Maintains | Outperform |
| 07/10/2023 | 34.15% | Citigroup | $22 → $23 | Maintains | Buy |
| 07/03/2023 | 34.15% | B of A Securities | $19 → $23 | Maintains | Buy |
| 07/03/2023 | 28.32% | HC Wainwright & Co. | → $22 | Reiterates | Buy → Buy |
| 05/30/2023 | 16.65% | Morgan Stanley | → $20 | Assumes | → Equal-Weight |
| 05/19/2023 | 28.32% | HC Wainwright & Co. | $19 → $22 | Maintains | Buy |
| 05/05/2023 | 10.82% | HC Wainwright & Co. | $21 → $19 | Maintains | Buy |
| 05/05/2023 | 4.99% | Barclays | $17 → $18 | Maintains | Equal-Weight |
| 05/04/2023 | 16.65% | RBC Capital | → $20 | Reiterates | → Outperform |
| 03/23/2023 | 22.48% | HC Wainwright & Co. | → $21 | Reiterates | → Buy |
| 03/09/2023 | — | Needham | Initiates Coverage On | → Hold | |
| 02/24/2023 | 22.48% | HC Wainwright & Co. | $20 → $21 | Maintains | Buy |
| 02/23/2023 | -0.85% | JP Morgan | $15 → $17 | Maintains | Neutral |
| 02/23/2023 | 16.65% | Morgan Stanley | $18 → $20 | Maintains | Equal-Weight |
| 02/23/2023 | 16.65% | RBC Capital | → $20 | Reiterates | → Outperform |
| 02/15/2023 | 16.65% | RBC Capital | $17 → $20 | Maintains | Outperform |
| 02/02/2023 | 16.65% | HC Wainwright & Co. | → $20 | Reiterates | → Buy |
| 12/21/2022 | -0.85% | Barclays | → $17 | Initiates Coverage On | → Equal-Weight |
| 11/23/2022 | -0.85% | Goldman Sachs | $19 → $17 | Maintains | Neutral |
| 11/03/2022 | -12.51% | JP Morgan | $16 → $15 | Maintains | Neutral |
| 11/03/2022 | -0.85% | RBC Capital | $18 → $17 | Maintains | Outperform |
| 11/03/2022 | 4.99% | Morgan Stanley | $19 → $18 | Maintains | Equal-Weight |
| 11/03/2022 | 16.65% | HC Wainwright & Co. | $21 → $20 | Maintains | Buy |
| 10/11/2022 | 10.82% | Morgan Stanley | $20 → $19 | Maintains | Equal-Weight |
| 09/12/2022 | 22.48% | HC Wainwright & Co. | → $21 | Initiates Coverage On | → Buy |
| 08/16/2022 | 10.82% | Goldman Sachs | $22 → $19 | Maintains | Neutral |
| 07/26/2022 | 28.32% | RBC Capital | → $22 | Initiates Coverage On | → Outperform |
| 06/24/2022 | 22.48% | Evercore ISI Group | → $21 | Initiates Coverage On | → Outperform |
| 06/09/2022 | 16.65% | Morgan Stanley | $22 → $20 | Maintains | Equal-Weight |
| 06/06/2022 | 28.32% | Citigroup | → $22 | Initiates Coverage On | → Buy |
| 05/31/2022 | 28.32% | Morgan Stanley | → $22 | Initiates Coverage On | → Equal-Weight |
| 05/31/2022 | 28.32% | Goldman Sachs | → $22 | Initiates Coverage On | → Neutral |
| 05/31/2022 | 39.98% | Guggenheim | → $24 | Initiates Coverage On | → Buy |
| 05/31/2022 | 34.15% | Wells Fargo | → $23 | Initiates Coverage On | → Overweight |
| 05/11/2022 | 104.14% | Cowen & Co. | → $35 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 10/06/2023 | 22.48% | HC Wainwright公司 | $22→$21 | 重申 | 購買→購買 |
| 10/03/2023 | 16.65% | Evercore ISI集團 | →$20 | 恢復 | →跑贏大盤 |
| 08/04/2023 | 28.32% | HC Wainwright公司 | →$22 | 重申 | 購買→購買 |
| 08/03/2023 | 16.65% | 摩根士丹利 | $20→$20 | 重申 | 等重→等重 |
| 08/03/2023 | 10.82% | 巴克萊 | $18→$19 | 維護 | 等重 |
| 07/24/2023 | 22.48% | 加拿大皇家銀行資本 | $20→$21 | 維護 | 跑贏大盤 |
| 07/10/2023 | 34.15% | 花旗集團 | $22→$23 | 維護 | 買 |
| 07/03/2023 | 34.15% | B of A證券 | $19→$23 | 維護 | 買 |
| 07/03/2023 | 28.32% | HC Wainwright公司 | →$22 | 重申 | 購買→購買 |
| 2023年05月30日 | 16.65% | 摩根士丹利 | →$20 | 假設 | →等重 |
| 2023年05月19日 | 28.32% | HC Wainwright公司 | $19→$22 | 維護 | 買 |
| 05/05/2023 | 10.82% | HC Wainwright公司 | $21→$19 | 維護 | 買 |
| 05/05/2023 | 4.99% | 巴克萊 | $17→$18 | 維護 | 等重 |
| 05/04/2023 | 16.65% | 加拿大皇家銀行資本 | →$20 | 重申 | →跑贏大盤 |
| 03/23/2023 | 22.48% | HC Wainwright公司 | →$21 | 重申 | →購買 |
| 03/09/2023 | - | 李約瑟 | 開始承保 | →保留 | |
| 02/24/2023 | 22.48% | HC Wainwright公司 | $20→$21 | 維護 | 買 |
| 02/23/2023 | -0.85% | 摩根大通 | $15→$17 | 維護 | 中性 |
| 02/23/2023 | 16.65% | 摩根士丹利 | $18→$20 | 維護 | 等重 |
| 02/23/2023 | 16.65% | 加拿大皇家銀行資本 | →$20 | 重申 | →跑贏大盤 |
| 02/15/2023 | 16.65% | 加拿大皇家銀行資本 | $17→$20 | 維護 | 跑贏大盤 |
| 02/02/2023 | 16.65% | HC Wainwright公司 | →$20 | 重申 | →購買 |
| 2022年12月21日 | -0.85% | 巴克萊 | →$17 | 開始承保 | →等重 |
| 2022年11月23日 | -0.85% | 高盛 | $19→$17 | 維護 | 中性 |
| 11/03/2022 | -12.51% | 摩根大通 | $16→$15 | 維護 | 中性 |
| 11/03/2022 | -0.85% | 加拿大皇家銀行資本 | $18→$17 | 維護 | 跑贏大盤 |
| 11/03/2022 | 4.99% | 摩根士丹利 | $19→$18 | 維護 | 等重 |
| 11/03/2022 | 16.65% | HC Wainwright公司 | $21→$20 | 維護 | 買 |
| 2022年10月11日 | 10.82% | 摩根士丹利 | $20→$19 | 維護 | 等重 |
| 09/12/2022 | 22.48% | HC Wainwright公司 | →$21 | 開始承保 | →購買 |
| 08/16/2022 | 10.82% | 高盛 | $22→$19 | 維護 | 中性 |
| 07/26/2022 | 28.32% | 加拿大皇家銀行資本 | →$22 | 開始承保 | →跑贏大盤 |
| 2022/06/24 | 22.48% | Evercore ISI集團 | →$21 | 開始承保 | →跑贏大盤 |
| 06/09/2022 | 16.65% | 摩根士丹利 | $22→$20 | 維護 | 等重 |
| 06/06/2022 | 28.32% | 花旗集團 | →$22 | 開始承保 | →購買 |
| 2022年05月31日 | 28.32% | 摩根士丹利 | →$22 | 開始承保 | →等重 |
| 2022年05月31日 | 28.32% | 高盛 | →$22 | 開始承保 | →中性 |
| 2022年05月31日 | 39.98% | 古根海姆 | →$24 | 開始承保 | →購買 |
| 2022年05月31日 | 34.15% | 富國銀行 | →$23 | 開始承保 | →超重 |
| 2022年05月11日 | 104.14% | 考恩公司 | →$35 | 開始承保 | →跑贏大盤 |
What is the target price for Bausch & Lomb (BLCO)?
博士倫的目標價是多少？
The latest price target for Bausch & Lomb (NYSE: BLCO) was reported by HC Wainwright & Co. on October 6, 2023. The analyst firm set a price target for $21.00 expecting BLCO to rise to within 12 months (a possible 22.48% upside). 29 analyst firms have reported ratings in the last year.
博士倫(紐約證券交易所代碼：BLCO)的最新目標價是由HC Wainwright&Co.於2023年10月6日報道的。這家分析公司將目標價定為21.00美元，預計BLCO將在12個月內上漲至22.48%(可能上漲22.48%)。去年有29家分析公司公佈了評級。
What is the most recent analyst rating for Bausch & Lomb (BLCO)?
博士倫(Bausch&Lomb)最近的分析師評級是多少？
The latest analyst rating for Bausch & Lomb (NYSE: BLCO) was provided by HC Wainwright & Co., and Bausch & Lomb reiterated their buy rating.
博士倫(紐約證券交易所代碼：BLCO)的最新分析師評級是由HC Wainwright&Co.提供的，博士倫重申了他們的買入評級。
When is the next analyst rating going to be posted or updated for Bausch & Lomb (BLCO)?
博士倫(Bausch&Lomb)的下一次分析師評級何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bausch & Lomb, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bausch & Lomb was filed on October 6, 2023 so you should expect the next rating to be made available sometime around October 6, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查看公開的財務報表，與博士倫的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。博士倫的上一次評級是在2023年10月6日提交的，因此你應該預計下一次評級將在2024年10月6日左右公佈。
Is the Analyst Rating Bausch & Lomb (BLCO) correct?
分析師對博士倫的評級正確嗎？
While ratings are subjective and will change, the latest Bausch & Lomb (BLCO) rating was a reiterated with a price target of $22.00 to $21.00. The current price Bausch & Lomb (BLCO) is trading at is $17.15, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但博士倫(BLCO)的最新評級重申了目標價在22.00美元至21.00美元之間。博士倫目前的股價為17.15美元，超出了分析師的預期區間。
譯文內容由第三人軟體翻譯。